Friday, July 28, 2017 5:56:53 PM
I won't say much about their marketing strategy because it's poorly executed, hence, the on-going drop for the last several months - that's just bad management on that part. However, their expertise is in clinical trails. I think this is where they will prove a lot of doubters wrong. An oak tree doesn't grow overnight. Just gotta wait for its time. I'm staying tuned to this David vs Goliath story...only time will tell.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM